Literature DB >> 25312732

Overview of green tea interaction with cardiovascular drugs.

José P Werba, Shingen Misaka, Monica G Giroli, Shizuo Yamada, Viviana Cavalca, Keisuke Kawabe, Isabella Squellerio, Federica Laguzzi, Satomi Onoue, Fabrizio Veglia, Veronika Myasoedova, Kazuhiko Takeuchi, Eisuke Adachi, Naoki Inui, Elena Tremoli, Hiroshi Watanabe1.   

Abstract

Sensitive to the massive diffusion of purported metabolic and cardiovascular positive effects of green tea and catechincontaining extracts, many consumers of cardiovascular drugs assume these products as a "natural" and presumably innocuous adjunctive way to increase their overall health. However, green tea may interfere with the oral bioavailability or activity of cardiovascular drugs by various mechanisms, potentially leading to reduced drug efficacy or increased drug toxicity. Available data about interactions between green tea and cardiovascular drugs in humans, updated in this review, are limited so far to warfarin, simvastatin and nadolol, and suggest that the average effects are mild to modest. Nevertheless, in cases of unexpected drug response or intolerance, it is warranted to consider a possible green tea-drug interaction, especially in people who assume large volumes of green tea and/or catechin-enriched products with the conviction that "more-is-better".

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25312732     DOI: 10.2174/1381612820666141013135045

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  8 in total

Review 1.  Antioxidants from black and green tea: from dietary modulation of oxidative stress to pharmacological mechanisms.

Authors:  Ilaria Peluso; Mauro Serafini
Journal:  Br J Pharmacol       Date:  2016-11-12       Impact factor: 8.739

2.  Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers.

Authors:  Shingen Misaka; Osamu Abe; Hideyuki Sato; Tomoyuki Ono; Yayoi Shikama; Satomi Onoue; Hirooki Yabe; Junko Kimura
Journal:  Eur J Clin Pharmacol       Date:  2018-01-24       Impact factor: 2.953

3.  The Influence of EGCG on the Pharmacokinetics and Pharmacodynamics of Bisoprolol and a New Method for Simultaneous Determination of EGCG and Bisoprolol in Rat Plasma.

Authors:  Weiwei Zeng; Sixian Lao; Yi Guo; Yufeng Wu; Min Huang; Brian Tomlinson; Guoping Zhong
Journal:  Front Nutr       Date:  2022-05-31

4.  Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein.

Authors:  Jana Knop; Shingen Misaka; Katrin Singer; Eva Hoier; Fabian Müller; Hartmut Glaeser; Jörg König; Martin F Fromm
Journal:  PLoS One       Date:  2015-10-01       Impact factor: 3.240

Review 5.  Antioxidant, Immunomodulating, and Microbial-Modulating Activities of the Sustainable and Ecofriendly Spirulina.

Authors:  Alberto Finamore; Maura Palmery; Sarra Bensehaila; Ilaria Peluso
Journal:  Oxid Med Cell Longev       Date:  2017-01-15       Impact factor: 6.543

6.  Effect of epigallocatechin-3-gallate, major ingredient of green tea, on the pharmacokinetics of rosuvastatin in healthy volunteers.

Authors:  Tae-Eun Kim; Na Ha; Yunjeong Kim; Hyunsook Kim; Jae Wook Lee; Ji-Young Jeon; Min-Gul Kim
Journal:  Drug Des Devel Ther       Date:  2017-05-09       Impact factor: 4.162

Review 7.  Pharmacokinetic Interactions between Cardiovascular Medicines and Plant Products.

Authors:  Irina-Iuliana Costache; Anca Miron; Monica Hăncianu; Viviana Aursulesei; Alexandru Dan Costache; Ana Clara Aprotosoaie
Journal:  Cardiovasc Ther       Date:  2019-09-02       Impact factor: 3.023

Review 8.  Update of green tea interactions with cardiovascular drugs and putative mechanisms.

Authors:  José Pablo Werba; Shingen Misaka; Monica Gianna Giroli; Kenju Shimomura; Manuela Amato; Niccolò Simonelli; Lorenzo Vigo; Elena Tremoli
Journal:  J Food Drug Anal       Date:  2018-02-14       Impact factor: 6.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.